Julien Nono-Womdim, Vice President, Equity Analysis, Goodreid Investment Counsel
Focus: U.S. Equities
Top Picks: TG Therapeutics, Medpace Holdings, United Natural Foods
MARKET OUTLOOK:
Tons of damage under the surface: The technology-heavy Nasdaq 100 is down over 10 per cent from its October high. The S&P 500 is only modestly off its highs but more than 50 per cent of its members are down 20 per cent or more from their record highs. The index is telling one story, and the average stock is telling another. From our perspective at Goodreid, we have seen a rapid and significant repricing of stocks driven by higher rates, geopolitical uncertainty in the Middle East and Europe, and risks with artificial intelligence (AI) spending. The midterms are now behind us, so that’s one less thing to worry about.
The case to be bullish starts with earnings: S&P 500 profits are expected to grow about a third this year and in the mid-teens next year, while the index trades at about 18 times forward earnings, down from about 22 at the start of the year. The biggest source of that growth is expected to remain the Technology sector, particularly companies benefiting from AI spending, followed by Health Care and Industrials. The debate is whether the spending earns appropriate returns. The biggest spenders have indicated favorable returns from AI spending and have raised capital to keep investing. Additionally, governments around the world now treat domestic AI as a priority, which should add a second source of demand.
The bear case is a chain reaction: If inflation stays elevated and the Fed has to keep hiking rates, a consumer who is already pessimistic could pull back. While the industrial economy remains strong, a weakening consumer economy could spiral into the industrial economy, leading to slower earnings growth or earnings that miss expectations.
In my written remarks in July, I said that volatility would be positive for active managers who understand the businesses they own. Since then, the index has held up while a large share of its members have fallen sharply. We have found the Health Care sector and Technology sector, particularly software, to be good hunting grounds for ideas. While bottoms are only apparent in hindsight, we believe the current environment is offering real opportunities.
- How to set BNN Bloomberg as your preferred source on Google
- Market-moving news, fast: Get the BNN Bloomberg App now
- Sign up for the Market Call Top Picks newsletter at bnnbloomberg.ca/newsletters
TOP PICKS:
TG Therapeutics (TGTX NASDAQ)
A catalyst rich biotechnology company. TGTX is a commercial-stage company whose multiple sclerosis drug, BRIUMVI, is crossing US$1 billion in annualized sales in the fast-growing class of anti-CD20 therapies. About 2.9 million people live with MS worldwide, roughly 1 million of them in the U.S.
We see a clear pathway to US$5 billion in peak sales in the early 2030s against consensus at peak sales arriving much later. Management estimates they will be exiting 2026 with a run rate above US$1 billion. The next inflector will be the subcutaneous (SubQ) version, with Phase 3 data expected within the next few months. If successful, it would open the more than a third of the market that favors self-administration, where TGTX does not compete today. On valuation, we assume over US$2 billion in revenues by 2029 and a 40 per cent net income margin, which gives about US$4.96 in EPS, and puts the stock at 12-13 times 2029 EPS, despite continued growth beyond. Single-product biotechnology companies carry real risk, but we view the risk/reward as compelling.
Medpace Holdings (MEDP NASDAQ)
An enabler and beneficiary of biotechnology innovation. Medpace Holdings is a leading clinical contract research organization, or CRO. The company provides outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. MEDP is differentiated in that it is the partner of choice for small and midsized biopharma companies given its full suite of services from Phase I-IV clinical trials. MEDP benefits from two tailwinds. First, the sector has structurally shifted from in-house clinical research among biopharma companies to an outsourced model. Second, we believe biopharma R&D is in a cyclical recovery, with bookings improving, and AI-driven discovery should put more drugs in trials over time. At 33 times forward earnings, MEDP trades at a premium multiple, which we think the secular growth justifies. The risk is another downturn in biotech funding, which would hit bookings first.
United Natural Foods (UNFI NYSE)
A recession-resistant turnaround. UNFI is a wholesale food distributor with a leading position in organic food distribution within the U.S. We like the food distribution business as it is a consolidated industry that has historically been resistant to economic cycles. With respect to UNFI specifically, we are encouraged by consumer trends in natural and organic food categories and the operational improvements undertaken by the company in recent years. The company generates approximately US$300 million in annual free cash flow against a US$3.1 billion market capitalization. At approximately 10 times FCF, we believe the valuation is undemanding given its underlying stability and industry attractiveness.
| DISCLOSURE | PERSONAL | FAMILY | PORTFOLIO/FUND |
|---|---|---|---|
| TGTX NASD | Y | Y | Y |
| MEDP NASD | N | N | Y |
| UNFI NYSE | N | N | Y |
PAST PICKS: FEB. 10, 2026
Citigroup (C NYSE)
Then: US$122.15
Now: US$119.73
Return: -2%
Total Return: -0.3%
Merck (MRK NYSE)
Then: US$117.15
Now: US$141.09
Return: 20%
Total Return: 23%
Celestica (CLS NYSE)
Then: US$297.93
Now: US$245.42
Return: -18%
Total Return: -18%
Total Return Average: 2%
| DISCLOSURE | PERSONAL | FAMILY | PORTFOLIO/FUND |
|---|---|---|---|
| C NYSE | N | N | Y |
| MRK NYSE | N | N | Y |
| CLS NYSE | Y | Y | Y |

